產(chǎn)品名稱

Netupitant - Ro 67-31898

產(chǎn)品貨號(hào)

Axon 2499 CAS [290297-26-6] MF C30H32F6N4OMW 578.59 Purity: 99% Soluble in 0.1N HCl(aq) and DMSO Description Highly selective NK 1 receptor antagonist. Approved drug in combination with Palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV). KEYWORDS: Netupitant | supplier | RO 67-31898 |

產(chǎn)品價(jià)格

現(xiàn)貨詢價(jià)，電話：010-67529703

產(chǎn)品規(guī)格

產(chǎn)品品牌

axonmedchem

產(chǎn)品概述

產(chǎn)品詳情

Netupitant - Ro 67-31898

Based on 14 reference(s) in Google Scholar 8 10 14

Axon 2499

CAS [290297-26-6]

MF C30H32F6N4O
MW 578.59

Purity: 99%
Soluble in 0.1N HCl(aq) and DMSO

Netupitant

Description

Highly selective NK 1 receptor antagonist. Approved drug in combination with Palonosetron (clinically and pharmacologically distinct 5-HT3 receptor antagonist) indicated for the prevention of chemotherapy-induced nausea and vomiting (CINV).

T. Hoffmann et al. Design and synthesis of a novel, achiral class of highly potent and selective, orally active neurokinin-1 receptor antagonists. Bioorg Med Chem Lett. 2006 Mar 1;16(5):1362-5.

P.J. Hesketh et al. Efficacy and safety of NEPA, an oral combination of netupitant and palonosetron, for prevention of chemotherapy-induced nausea and vomiting following highly emetogenic chemotherapy.... Ann Oncol. 2014 Jul;25(7):1340-6.?

M. Stathis et al. Inhibition of substance P-mediated responses in NG108-15 cells by netupitant and palonosetron exhibit synergistic effects. Eur J Pharmacol. 2012 Aug 15;689(1-3):25-30.

Certificate of Analysis
Material Safety Data Sheet

CNS Diabetes & Metabolism Pain & Inflammation A9 Tachykinin (NK)

Selective NK1 antagonist; Prevents chemotherapy-induced nausea and vomiting

Chemical name

2-(3,5-bis(trifluoromethyl)phenyl)-N,2-dimethyl-N-(6-(4-methylpiperazin-1-yl)-4-o-tolylpyridin-3-yl)propanamide

Parent CAS No.

[290297-26-6]

產(chǎn)品資料